| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
|
Blood
|
2008
|
7.01
|
|
2
|
Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells.
|
Blood
|
2009
|
7.00
|
|
3
|
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.
|
J Clin Invest
|
2008
|
6.15
|
|
4
|
Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit.
|
Blood
|
2009
|
3.05
|
|
5
|
Overlap and effective size of the human CD8+ T cell receptor repertoire.
|
Sci Transl Med
|
2010
|
3.01
|
|
6
|
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
|
Blood
|
2012
|
2.97
|
|
7
|
Molecules and mechanisms of the graft-versus-leukaemia effect.
|
Nat Rev Cancer
|
2004
|
2.65
|
|
8
|
A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy.
|
Immunity
|
2009
|
2.64
|
|
9
|
Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice.
|
Blood
|
2010
|
2.61
|
|
10
|
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.
|
Blood
|
2010
|
2.59
|
|
11
|
Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.
|
Blood
|
2002
|
2.48
|
|
12
|
Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.
|
Blood
|
2010
|
2.45
|
|
13
|
Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation.
|
Blood
|
2005
|
2.39
|
|
14
|
CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.
|
Blood
|
2013
|
2.22
|
|
15
|
Redox regulation facilitates optimal peptide selection by MHC class I during antigen processing.
|
Cell
|
2006
|
2.20
|
|
16
|
An antigen produced by splicing of noncontiguous peptides in the reverse order.
|
Science
|
2006
|
2.18
|
|
17
|
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.
|
Blood
|
2011
|
2.15
|
|
18
|
Safety and immunologic effects of IL-15 administration in nonhuman primates.
|
Blood
|
2009
|
2.00
|
|
19
|
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants.
|
Blood
|
2003
|
1.93
|
|
20
|
CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients.
|
J Exp Med
|
2004
|
1.92
|
|
21
|
Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells.
|
Blood
|
2010
|
1.88
|
|
22
|
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.
|
Clin Cancer Res
|
2013
|
1.85
|
|
23
|
Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus.
|
J Clin Invest
|
2002
|
1.79
|
|
24
|
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
|
J Clin Invest
|
2016
|
1.75
|
|
25
|
HapMap scanning of novel human minor histocompatibility antigens.
|
Blood
|
2008
|
1.75
|
|
26
|
Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.
|
Clin Cancer Res
|
2009
|
1.74
|
|
27
|
Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy.
|
Hum Gene Ther
|
2007
|
1.70
|
|
28
|
Induction of cytotoxic T-lymphocyte responses to enhanced green and yellow fluorescent proteins after myeloablative conditioning.
|
Blood
|
2003
|
1.61
|
|
29
|
A human minor histocompatibility antigen resulting from differential expression due to a gene deletion.
|
J Exp Med
|
2003
|
1.61
|
|
30
|
Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production.
|
J Exp Med
|
2003
|
1.55
|
|
31
|
Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.
|
Blood
|
2011
|
1.54
|
|
32
|
Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.
|
J Immunother
|
2012
|
1.47
|
|
33
|
Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation.
|
Blood
|
2002
|
1.47
|
|
34
|
Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation.
|
Blood
|
2003
|
1.47
|
|
35
|
Human cytomegalovirus microRNA miR-US4-1 inhibits CD8(+) T cell responses by targeting the aminopeptidase ERAP1.
|
Nat Immunol
|
2011
|
1.46
|
|
36
|
Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
|
Clin Cancer Res
|
2004
|
1.42
|
|
37
|
Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection.
|
Blood
|
2004
|
1.42
|
|
38
|
Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells.
|
Cancer Res
|
2009
|
1.37
|
|
39
|
Adoptive transfer of virus-specific and tumor-specific T cell immunity.
|
Curr Opin Immunol
|
2009
|
1.36
|
|
40
|
Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells.
|
Proc Natl Acad Sci U S A
|
2005
|
1.36
|
|
41
|
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.
|
Immunol Rev
|
2014
|
1.33
|
|
42
|
Highly efficient gene transfer into baboon marrow repopulating cells using GALV-pseudotype oncoretroviral vectors produced by human packaging cells.
|
Blood
|
2002
|
1.24
|
|
43
|
Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein.
|
J Immunol
|
2003
|
1.21
|
|
44
|
C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.
|
Clin Cancer Res
|
2008
|
1.20
|
|
45
|
HLA engineering of human pluripotent stem cells.
|
Mol Ther
|
2013
|
1.19
|
|
46
|
Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus.
|
J Exp Med
|
2009
|
1.19
|
|
47
|
Enhanced transgene expression in quiescent and activated human CD8+ T cells.
|
Hum Gene Ther
|
2004
|
1.19
|
|
48
|
The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL.
|
Blood
|
2006
|
1.17
|
|
49
|
Innate signals overcome acquired TCR signaling pathway regulation and govern the fate of human CD161(hi) CD8α⁺ semi-invariant T cells.
|
Blood
|
2011
|
1.16
|
|
50
|
Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia.
|
Immunol Cell Biol
|
2011
|
1.14
|
|
51
|
Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.
|
J Clin Invest
|
2015
|
1.13
|
|
52
|
Engineered T cells for anti-cancer therapy.
|
Curr Opin Immunol
|
2012
|
1.12
|
|
53
|
Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imaging.
|
Mol Ther
|
2009
|
1.11
|
|
54
|
Generation of HIV-1-specific CD8+ cell responses following allogeneic hematopoietic cell transplantation.
|
Blood
|
2008
|
1.10
|
|
55
|
National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.
|
Biol Blood Marrow Transplant
|
2011
|
1.09
|
|
56
|
Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo.
|
Blood
|
2013
|
1.06
|
|
57
|
Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model.
|
Blood
|
2003
|
1.06
|
|
58
|
Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy.
|
Curr Opin Immunol
|
2011
|
1.04
|
|
59
|
TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer.
|
Sci Transl Med
|
2013
|
1.02
|
|
60
|
DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells.
|
Blood
|
2008
|
1.01
|
|
61
|
A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation.
|
Br J Haematol
|
2005
|
1.00
|
|
62
|
Artificial antigen-presenting cells for use in adoptive immunotherapy.
|
Cancer J
|
2010
|
1.00
|
|
63
|
Association between immune recovery uveitis and a diverse intraocular cytomegalovirus-specific cytotoxic T cell response.
|
J Infect Dis
|
2002
|
0.99
|
|
64
|
Novel serial positive enrichment technology enables clinical multiparameter cell sorting.
|
PLoS One
|
2012
|
0.98
|
|
65
|
Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
0.96
|
|
66
|
Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
0.95
|
|
67
|
Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling.
|
Br J Haematol
|
2003
|
0.95
|
|
68
|
Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1.
|
Cancer Res
|
2006
|
0.93
|
|
69
|
HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway.
|
J Immunol
|
2013
|
0.92
|
|
70
|
CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy.
|
Blood
|
2002
|
0.92
|
|
71
|
A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403.
|
Transplantation
|
2007
|
0.91
|
|
72
|
Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.
|
Cancer Immunol Immunother
|
2011
|
0.91
|
|
73
|
Adoptive T-cell therapy for B-cell malignancies.
|
Expert Rev Hematol
|
2009
|
0.88
|
|
74
|
Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation.
|
Biol Blood Marrow Transplant
|
2005
|
0.84
|
|
75
|
Targeted cloning of cytotoxic T cells specific for minor histocompatibility antigens restricted by HLA class I molecules of interest.
|
Transplantation
|
2002
|
0.82
|
|
76
|
Proliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaques.
|
PLoS One
|
2013
|
0.80
|
|
77
|
Double unit cord blood transplantation: Who wins-and why do we care?
|
Chimerism
|
2016
|
0.80
|
|
78
|
Immunologic predictors of late cytomegalovirus disease after solid organ transplantation--an elusive goal?
|
J Infect Dis
|
2007
|
0.79
|
|
79
|
HIV-1 Vpr does not inhibit CTL-mediated apoptosis of HIV-1 infected cells.
|
Virology
|
2002
|
0.79
|
|
80
|
Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.
|
Expert Rev Hematol
|
2012
|
0.77
|
|
81
|
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia.
|
J Clin Invest
|
2016
|
0.75
|
|
82
|
Genetic modification of T cells for immunotherapy.
|
Expert Opin Biol Ther
|
2007
|
0.75
|